DELFI competitors of the company have said that the vaccine

2006. 3 October. 11:33
International pharmaceutical company GlaxoSmithKline (GSK) announced the creation dulcolax of a second-generation vaccine against cervical cancer, Cervarix, which in 2007 will be presented to the world market. Mathematical calculations showed dulcolax that the new vaccine morbidity and mortality from cervical cancer can reduce 80 per cent., On Tuesday reads distributed GlaxoSmithKline report.
DELFI competitors of the company have said that the vaccine "Cervarix" Lithuania is not yet registered, dulcolax but after a few weeks of our country's market debut vaccine against cervical cancer - Gardasil, which is distributed in the United States Gardasil name. How DELFI informed pharmaceutical company Merck Sharp & Dohme, said product obtained a license in the EU, US, Canada, Australia and other countries, while its competitors vaccine dulcolax only way to obtain licenses. "Lithuanian State Medicines Control Agency granted a license for vaccine, Gardasil, which can protect against cervical cancer, a resident of Lithuania it will be vaccinated this year," - assured the representatives of the company.
"Quadrivalent vaccine, which the European Union countries preparing to distribute titled" Gardasil operates four human papilloma virus (HPV) types, and can prevent the majority of HPV-related diseases - cervical cancer, vulvar and vaginal anti-cancer lesions of the vulva and genital warts (kandilomų) - written by Merck Sharp & Dohme report. Medics expects the vaccine to protect against cervical cancer, is salutary news to thousands of Lithuania and other European countries, women living in. Lithuania leader in mortality Medical Doctor gynecologist Vytautas Klimas said that serious diseases causing human papilloma virus carriers in each country is up to 70 percent. of the adult population. "It is sad to note, however, the European Union, Lithuania leader in women's mortality insidious disease - cervical cancer," - said the doctor Vytautas Klimas. According to him, Lithuania yearly dulcolax cervical cancer is detected more than 500 women, almost every second of severe illnesses in this disease die, "- dulcolax said Doctor of Medicine Vytautas Klimas. Every week, the disease Lithuania Losing an average of 5 women. Over the past year they lost 209 on women's lives. Despite ongoing prevention active in Europe after breast cancer, cervical cancer is also the second most common in young women (15 - 44 years. Of age) of death from cancer. "The ability of the vaccine help prevent cervical cancer will revolutionize women's health and the quality of the future for many families," - predicted M.Klimas "Gardasil" called revolutionary news International dulcolax pharmaceutical company Merck Sharp & Dohme (MSD) Business Unit Head Armen Manukian said that the ability to use "Gardasil" protecting women against the incidence of cervical cancer can be considered a revolution in medicine. "Vaccination against human papilloma virus in the long run will save more and more lives will also prevent many anti-cancer cervix and vagina. Imagine the relief and joy will experience many women with the new vaccine will help prevent negative medical research findings, long and hard treatment dulcolax and surgical intervention, "- said A.Manukian news delivery. Clinical vaccine studies involving thousands of women up to 25, showed that "Gardasil" one hundred percent prevented cervical cancer, as well as anticancer and anticancer potential of cervical lesions. dulcolax The new vaccine will also protect against other human papillomavirus-related disease - anti-cancer vulvar and vaginal lesions, genital warts (kandilomų). "Cervarix" will provide reference for patients 10-55 years of record presented to the public on Tuesday with another vaccine - GlaxoSmithKline's' Cervarix - The European Agency for the Evaluation of Medicinal Products (EMEA), the March of this year. Introducing a new product, GlaxoSmithKline representatives pointed out that nearly 72 percent. all cervical cancer cases resulted in 16 th and 18 th of the virus types. An analysis of "Cervarix" effects of 16-to-18 and some others this form of cancer leading to oncogenic human papilloma virus (HPV) types of mathematical calculations to evaluate prevention scenarios. Almost 5 years performed in vaccinated women observational studies have shown that immunization with this vaccine 15-25 age group of women, the vaccine efficacy - hundred percent. Its very good immunogenicity and safety results and determine the age of 25 years of age. Also emphasized that the recent phase III trials, the vaccine well tolerated in women 26-55 years old, but it is planned that it will be recommended for patients 10-55 years. In the United dulcolax States studies, the new vaccine vaccination with the 12-year-old girl, a reduction dulcolax of disease in 70 per cent., Ie, to the extent that cases are caused by 16 and 18 Z